Description
Anti-Presenilin 1 Antibody, Non-Fucosylated (BioBet-1506ZP) is a Rabbit monoclonal IgG antibody against Presenilin 1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Alzheimer's Disease
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Presenilin 1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
Alzheimers disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1; PSEN2) or in the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor, such that they either directly regulate gamma-secretase activity or themselves are protease enzymes. Several alternatively spliced transcript variants encoding different isoforms have been identified for this gene, the full-length nature of only some have been determined. [provided by RefSeq, Aug 2008]
Alternative Names
PSEN1; presenilin 1; AD3; FAD; PS1; PS-1; S182; presenilin-1;
Cellular Localization
Golgi apparatus, Plasma membrane, Endosome, Endoplasmic reticulum
Involvement in Disease
Diseases associated with PSEN1 include Pick Disease Of Brain and Alzheimer Disease 3.
Related Pathways
Its related pathways are Neuroscience and Degradation of the extracellular matrix.
Function
The genetic disease form of Alzheimer's disease (AD) patients carries a mutated progeria protein (PSEN1; or in amyloid precursor protein (APP). These disease-related mutations increase amyloid protein (Amyloid in AD brain). The main component of protein deposition). Presenilin is hypothesized to regulate APP processing through the action of -secretase (an enzyme that cleaves APP). In addition, it is believed that presenilin is involved in the Notch receptor. Cleavage, so they either directly regulate secretase activity or are proteases themselves. Several alternatively spliced transcription variants encoding different subtypes of this gene have been identified, and only the full-length nature of some genes has been determined. [by RefSeq Provided, August 2008]
Post-translational modifications
1.Heterogeneous proteolytic processing generates N-terminal (NTF) and C-terminal (CTF) fragments of approximately 35 and 20 kDa, respectively. During apoptosis, the C-terminal fragment (CTF) is further cleaved by caspase-3 to produce the fragment, PS1-CTF12 2.Modification sites at PhosphoSitePlus 3.After endoproteolysis, the C-terminal fragment (CTF) is phosphorylated on serine residues by PKA and/or PKC. Phosphorylation on Ser-346 inhibits endoproteolysis
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-1506ZP
Description
Anti-Presenilin 1 antibody targets Pren, which is expressed in a wide range of tissues including various regions of the brain, liver, spleen and lymph nodes, may be used to treat for Alzheimer's Disease, cardiomyopathy dilated type 3, acne inversa familial type 3 (ACNIF3).
Antibody Indication
Alzheimer's Disease
